Minimally invasive extracorporeal circulation versus conventional cardiopulmonary bypass in patients undergoing cardiac surgery (MiECS): Rationale and design of a multicentre randomised trial

Basit Öğe Kaydı
dc.authoridPunjabi, Prof Prakash P/0000-0002-6587-1603
dc.authoridAntonitsis, Polychronis/0000-0002-5451-4651
dc.authoridBozok, Şahin/0000-0002-1256-5055
dc.authoridgunaydin, serdar/0000-0002-9717-9793
dc.contributor.authorAnastasiadis, Kyriakos
dc.contributor.authorAntonitsis, Polychronis
dc.contributor.authorPapazisis, Georgios
dc.contributor.authorHaidich, Bettina
dc.contributor.authorLiebold, Andreas
dc.contributor.authorPunjabi, Prakash
dc.contributor.authorGunaydin, Serdar
dc.date.accessioned2025-03-20T09:50:45Z
dc.date.available2025-03-20T09:50:45Z
dc.date.issued2024
dc.departmentİzmir Bakırçay Üniversitesi
dc.description.abstractIntroduction The ultimate answer to the question whether minimal invasive extracorporeal circulation (MiECC) represents the optimal perfusion technique in contemporary clinical practice remains elusive. The present study is a real-world study that focuses on specific perfusion-related clinical outcomes after cardiac surgery that could potentially be favourably affected by MiECC and thereby influence the future clinical practice.Methods The MiECS study is an international, multi-centre, two-arm randomized controlled trial. Patients undergoing elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or combined procedure (CABG + AVR) using extracorporeal circulation will be randomized to MiECC or contemporary conventional cardiopulmonary bypass (cCPB). Use of optimized conventional circuits as controls is acceptable. The study design includes a range of features to prevent bias and is registered at clinicaltrials.gov (NCT05487612).Results The primary outcome is a composite of postoperative serious adverse events that could be related to perfusion technique occurring up to 30 days postoperatively. Secondary outcomes include use of blood products, ICU and hospital length of stay (30 days) as well as health-related quality of life (30 and 90 days).Conclusions The MiECS trial has been designed to overcome perceived limitation of previous trials of MiECC. Results of the proposed study could affect current perfusion practice towards advancement of patient care.
dc.identifier.doi10.1177/02676591241272009
dc.identifier.issn0267-6591
dc.identifier.issn1477-111X
dc.identifier.pmid39089011
dc.identifier.scopus2-s2.0-85200230617
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1177/02676591241272009
dc.identifier.urihttps://hdl.handle.net/20.500.14034/2299
dc.identifier.wosWOS:001282501500001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.ispartofPerfusion-Uk
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250319
dc.subjectminimal invasive
dc.subjectextracorporeal circulation
dc.subjectcardiopulmonary bypass
dc.subjectcardiac surgery
dc.titleMinimally invasive extracorporeal circulation versus conventional cardiopulmonary bypass in patients undergoing cardiac surgery (MiECS): Rationale and design of a multicentre randomised trial
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu